BioAge Labs, Inc.
BIOA
Get informed when a big investor buys or sells
+ FollowMarket Cap$39.35B
Close$
$6.73
39.9% downside
Current Fair Value
39.9% downsideOvervalued by 39.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $39.35 Billion |
|---|---|
| Enterprise Value | $39.17 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.24 |
| Beta | 0.62 |
| Outstanding Shares | 42,480,488 |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | -3.77 |
|---|---|
| PEG | -0.66 |
| Price to Sales | - |
| Price to Book Ratio | 1.87 |
| Enterprise Value to Revenue | 2999.97 |
| Enterprise Value to EBIT | -521.18 |
| Enterprise Value to Net Income | -556 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.65
Average shareholder expectationRevenue Estimate
$720,000
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.65
Average shareholder expectationRevenue Estimate
$1.50 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 682.58% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.57%▼ 94.85% |
|---|---|
| Total Invested | $5.96M▼ 99.01% |
| Investors Holding | 21▼ 127.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...